Ascendis Pharma As Stock Market Value
| ASND Stock | USD 223.41 7.09 3.28% |
| Symbol | Ascendis |
Will Biotechnology sector continue expanding? Could Ascendis diversify its offerings? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ascendis Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.46) | Revenue Per Share | Quarterly Revenue Growth 0.423 | Return On Assets | Return On Equity |
Understanding Ascendis Pharma AS requires distinguishing between market price and book value, where the latter reflects Ascendis's accounting equity. The concept of intrinsic value - what Ascendis Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ascendis Pharma's price substantially above or below its fundamental value.
Understanding that Ascendis Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascendis Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Ascendis Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Ascendis Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ascendis Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ascendis Pharma.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in Ascendis Pharma on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding Ascendis Pharma AS or generate 0.0% return on investment in Ascendis Pharma over 90 days. Ascendis Pharma is related to or competes with Ionis Pharmaceuticals, BridgeBio Pharma, Revolution Medicines, Roivant Sciences, Summit Therapeutics, Guardant Health, and Madrigal Pharmaceuticals. Ascendis Pharma AS, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs More
Ascendis Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ascendis Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ascendis Pharma AS upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.42 | |||
| Information Ratio | 0.0536 | |||
| Maximum Drawdown | 12.8 | |||
| Value At Risk | (4.28) | |||
| Potential Upside | 4.74 |
Ascendis Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascendis Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ascendis Pharma's standard deviation. In reality, there are many statistical measures that can use Ascendis Pharma historical prices to predict the future Ascendis Pharma's volatility.| Risk Adjusted Performance | 0.0657 | |||
| Jensen Alpha | 0.1965 | |||
| Total Risk Alpha | 0.0416 | |||
| Sortino Ratio | 0.0577 | |||
| Treynor Ratio | (0.55) |
Ascendis Pharma February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0657 | |||
| Market Risk Adjusted Performance | (0.54) | |||
| Mean Deviation | 2.01 | |||
| Semi Deviation | 2.27 | |||
| Downside Deviation | 2.42 | |||
| Coefficient Of Variation | 1351.82 | |||
| Standard Deviation | 2.6 | |||
| Variance | 6.76 | |||
| Information Ratio | 0.0536 | |||
| Jensen Alpha | 0.1965 | |||
| Total Risk Alpha | 0.0416 | |||
| Sortino Ratio | 0.0577 | |||
| Treynor Ratio | (0.55) | |||
| Maximum Drawdown | 12.8 | |||
| Value At Risk | (4.28) | |||
| Potential Upside | 4.74 | |||
| Downside Variance | 5.83 | |||
| Semi Variance | 5.14 | |||
| Expected Short fall | (2.26) | |||
| Skewness | 0.0197 | |||
| Kurtosis | 0.2071 |
Ascendis Pharma AS Backtested Returns
At this point, Ascendis Pharma is very steady. Ascendis Pharma AS secures Sharpe Ratio (or Efficiency) of 0.0549, which signifies that the company had a 0.0549 % return per unit of standard deviation over the last 3 months. We have found twenty-eight technical indicators for Ascendis Pharma AS, which you can use to evaluate the volatility of the firm. Please confirm Ascendis Pharma's mean deviation of 2.01, and Risk Adjusted Performance of 0.0657 to double-check if the risk estimate we provide is consistent with the expected return of 0.14%. Ascendis Pharma has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.33, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Ascendis Pharma are expected to decrease at a much lower rate. During the bear market, Ascendis Pharma is likely to outperform the market. Ascendis Pharma AS right now shows a risk of 2.57%. Please confirm Ascendis Pharma AS value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall , to decide if Ascendis Pharma AS will be following its price patterns.
Auto-correlation | -0.05 |
Very weak reverse predictability
Ascendis Pharma AS has very weak reverse predictability. Overlapping area represents the amount of predictability between Ascendis Pharma time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ascendis Pharma AS price movement. The serial correlation of -0.05 indicates that only as little as 5.0% of current Ascendis Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.05 | |
| Spearman Rank Test | 0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 67.91 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Ascendis Pharma Correlation, Ascendis Pharma Volatility and Ascendis Pharma Performance module to complement your research on Ascendis Pharma. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Ascendis Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.